Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022

Video

Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Ira Winer, MD, PhD, FACOG, a gynecologic oncologist at the Karmanos Cancer Center and associate professor in the Division of Gynecologic Oncology at Wayne State University in Detroit, about the future of ovarian cancer treatment and ongoing trials that were presented at the conference that he’s eager to see results of.

Transcript:

The most interesting thing about SGO this year was the trajectory [showing] how much we’re moving towards targeted therapies and individualized therapies, even in the IO [immuno-oncology] realm, as well as the non-IO realm. If you listen, especially to some of the plenaries, you could hear that we’re really digging into the mechanistic complex of how these [tumors] work in terms of how their disease responds to these treatments. [Given that], we’ll be able to better target the cancers in the future, but also choose the right patients for the right treatment. That is the most exciting. Over the course of SGO, [presentations continually proved] how things are moving in that direction. Even in the IO realm, we had some secondary analyses of various trials to look at why perhaps patients responded versus didn’t respond. That’s going to allow us to better design our trials in the future, and also hopefully to better sequence treatments, whether it’s IO or not. That was the most exciting thing about this SGO.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content